Samantha C Gouw

List of Publications by Year
in descending order

54	2,626	361413	182427
papers	citations	20 h-index	51 g-index

55	55	55	1377
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood, 2007, 109, 4648-4654.	1.4	449
2	Factor VIII Products and Inhibitor Development in Severe Hemophilia A. New England Journal of Medicine, 2013, 368, 231-239.	27.0	383
3	F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood, 2012, 119, 2922-2934.	1.4	305
4	Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood, 2013, 121, 4046-4055.	1.4	287
5	Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood, 2007, 109, 4693-4697.	1.4	220
6	Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. Journal of Thrombosis and Haemostasis, 2007, 5, 1383-1390.	3.8	134
7	The Multifactorial Etiology of Inhibitor Development in Hemophilia: Genetics and Environment. Seminars in Thrombosis and Hemostasis, 2009, 35, 723-734.	2.7	101
8	IgG subclasses of antiâ€FVIII antibodies during immune tolerance induction in patients with hemophilia A. British Journal of Haematology, 2008, 142, 644-652.	2.5	82
9	Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001â€“2018. Journal of Thrombosis and Haemostasis, 2021, 19, 645-653.	3.8	48
10	Healthâ€related quality of life questionnaires in individuals with haemophilia: a systematic review of their measurement properties. Haemophilia, 2017, 23, 497-510.	2.1	43
11	Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients. Haemophilia, 2011, 17, 275-281.	2.1	39
12	Similar bleeding phenotype in young children with haemophilia A or B: a cohort study. Haemophilia, 2014, 20, 747-755.	2.1	35
13	Measurement of joint health in persons with haemophilia: A systematic review of the measurement properties of haemophiliaâ€specific instruments. Haemophilia, 2019, 25, e1-e10.	2.1	31
14	Patient Perspectives on Novel Treatments in Haemophilia: A Qualitative Study. Patient, 2020, 13, 201-210.	2.7	28
15	Prenatal diagnosis for haemophilia: a nationwide survey among female carriers in the Netherlands. Haemophilia, 2012, 18, 584-592.	2.1	25
16	FactorÂVIII products and inhibitor development in previously treated patients with severe or moderately severe hemophiliaÂA: a systematic review. Journal of Thrombosis and Haemostasis, 2018, 16, 1055-1068.	3.8	25
17	Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units. Haemophilia, 2010, 16, 71-79.	2.1	24
18	Identifying Nongenetic Risk Factors for Inhibitor Development in Severe Hemophilia A. Seminars in Thrombosis and Hemostasis, 2013, 39, 740-751.	2.7	24

#	Article	IF	Citations
19	Vaccinations are not associated with inhibitor development in boys with severe haemophilia A. Haemophilia, 2018, 24, 283-290.	2.1	24
20	Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis. Blood, 2021, 138, 2853-2873.	1.4	23
21	Measuring activities and participation in persons with haemophilia: A systematic review of commonly used instruments. Haemophilia, 2018, 24, e33-e49.	2.1	21
22	Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972â€“2019. Journal of Thrombosis and Haemostasis, 2021, 19, 2394-2406.	3.8	21
23	Patientâ€relevant health outcomes for hemophilia care: Development of an international standard outcomes set. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12488.	2.3	20
24	Joint status of patients with nonsevere hemophilia A. Journal of Thrombosis and Haemostasis, 2022, 20, 1126-1137.	3.8	17
25	Validation of PROMIS Profileâ€29 in adults with hemophilia in the Netherlands. Journal of Thrombosis and Haemostasis, 2021, 19, 2687-2701.	3.8	16
26	Secondâ€generation recombinant factor <scp>VIII</scp> and inhibitor risk: interpretation of <scp>RODIN</scp> study findings and implications for patients with haemophilia A. Haemophilia, 2014, 20, e171-4.	2.1	15
27	The factor VIII treatment history of nonâ€severe hemophilia A. Journal of Thrombosis and Haemostasis, 2020, 18, 3203-3210.	3.8	15
28	Similar sports participation as the general population in Dutch persons with haemophilia; results from a nationwide study. Haemophilia, 2021, 27, 876-885.	2.1	14
29	Prevalence and Incidence of Non-neutralizing Antibodies in Congenital Hemophilia Aâ€" A Systematic Review and Meta-Analysis. Frontiers in Immunology, 2020, 11, 563.	4.8	12
30	Factor VIII Products and Inhibitors in Severe Hemophilia A. New England Journal of Medicine, 2013, 368, 1456-1457.	27.0	11
31	Patientâ€centred care in haemophilia: Patient perspectives on visualization and participation in decisionâ€making. Haemophilia, 2019, 25, 938-945.	2.1	11
32	Discordant antibody response in monozygotic twins with severe haemophilia A caused by intensive treatment. Haemophilia, 2009, 15, 712-717.	2.1	10
33	The bleeding phenotype in people with nonsevere hemophilia. Blood Advances, 2022, 6, 4256-4265.	5.2	10
34	Preventing or Eradicating Factor VIII Antibody Formation in Patients with Hemophilia A: What Can We Learn from Other Disorders?. Seminars in Thrombosis and Hemostasis, 2018, 44, 531-543.	2.7	9
35	Postpartum haemorrhage in an unselected cohort of carriers of haemophilia. Haemophilia, 2018, 24, e256-e259.	2.1	8
36	Adherence to prophylaxis and its association with activation of selfâ€management and treatment satisfaction. Haemophilia, 2021, 27, 581-590.	2.1	8

#	Article	IF	Citations
37	Treatmentâ€related risk factors for inhibitor development in nonâ€severe hemophilia A after 50 cumulative exposure days: A caseâ€control study. Journal of Thrombosis and Haemostasis, 2021, 19, 2171-2181.	3.8	8
38	Generic PROMIS item banks in adults with hemophilia for patientâ€reported outcome assessment: Feasibility, measurement properties, and relevance. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12621.	2.3	8
39	Patientâ€reported outcomes in autosomal inherited bleeding disorders: A systematic literature review. Haemophilia, 2022, 28, 197-214.	2.1	7
40	Hemophilia management: Huge impact of a tiny difference. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 377-385.	2.3	6
41	Cardiovascular risk factors among adult patients with haemophilia. International Journal of Hematology, 2021, 113, 884-892.	1.6	6
42	SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders. Journal of Thrombosis and Haemostasis, 2022, 20, 2001-2011.	3.8	6
43	Response: Plasma-derived or recombinant factor VIII products and inhibitors in previously untreated patients with severe hemophilia. Blood, 2007, 110, 1074-1075.	1.4	5
44	Inhibitor incidence in haemophilia A under exclusive use of a thirdâ€generation recombinant factor <scp>VIII</scp> concentrate: results of the <scp>HEMFIL</scp> Cohort Study. British Journal of Haematology, 2019, 186, 152-155.	2.5	5
45	Prophylactic anticoagulation in children receiving home parenteral nutrition. Journal of Parenteral and Enteral Nutrition, 2021, , .	2.6	5
46	Antibody therapies for lymphoma in children. The Cochrane Library, 2016, 2016, CD011181.	2.8	4
47	Unraveling the genetics of inhibitors in hemophilia. Blood, 2013, 121, 1250-1251.	1.4	3
48	Sports participation is not associated with adherence to prophylaxis in Dutch patients with haemophilia. Haemophilia, 2021, 27, e402-e405.	2.1	3
49	Hepatitis C virus in hemophilia: Healthâ€related quality of life after successful treatment in the sixth Hemophilia in the Netherlands study. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12616.	2.3	3
50	Measuring anxiety and depression in young adult men with haemophilia using PROMIS. Haemophilia, 2022, 28, .	2.1	3
51	Myocardial infarction due to thrombotic occlusion despite anticoagulation in Kawasaki disease â€“ a case report. BMC Pediatrics, 2022, 22, 85.	1.7	2
52	Response: Immunogenicity of factor VIII concentrates in patients with hemophilia: the next sensible step. Blood, 2007, 110, 3085-3085.	1.4	1
53	Defining patient value in haemophilia care. Haemophilia, 2018, 24, 516-518.	2.1	1
54	The factor VIII treatment history of nonâ€severe hemophilia Aâ€"Response from original authors Abdi et al. Journal of Thrombosis and Haemostasis, 2021, 19, 2642-2644.	3.8	1